Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.54 |
| ▸ | MGLL | Q99685 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979623 | 0.87 | FAAH (0.57) | FAAHCYP1A2 | |
| SCHEMBL17082349 | 0.85 | FAAH (0.55) | FAAH | |
| SCHEMBL17082365 | 0.85 | FAAH (0.58) | FAAH | |
| SCHEMBL518160 | 0.81 | FAAH (0.48) | FAAHMGLLCYP1A2CYP2D6TRPV1 | |
| SCHEMBL518294 | 0.81 | FAAH (0.46) | FAAHMGLLCYP1A2CYP2D6TRPV1 | |
| SCHEMBL3417556 | 0.79 | FAAH (0.66) | FAAH | |
| SCHEMBL13692025 | 0.73 | FAAH (0.47) | FAAHMGLLCYP1A2CYP2D6 | |
| SCHEMBL517579 | 0.70 | FAAH (1.00) | FAAH | |
| SCHEMBL517913 | 0.70 | FAAH (0.72) | FAAH | |
| SCHEMBL29427570 | 0.70 | FAAH (1.00) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12246014-B2 | Azetidine derivatives | LIGAND UK DEVELOPMENT LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-10918640-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | disclosed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | disclosed |
| EP-2265578-B1 | AZETIDINE DERIVATIVES | VERNALIS R&D LTD (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20130331371-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2013-12-12 | — | — | US | disclosed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | disclosed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20120028953-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2012-02-02 | — | — | US | disclosed |
| US-20120028953-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2012-02-02 | — | — | US | disclosed |
| EP-2265578-A1 | AZETIDINE DERIVATIVES | Vernalis (R&D) Ltd. (GB) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009109743-A1 | AZETIDINE DERIVATIVES | VERNALIS (R&D) LTD. (GB) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109743-A1 | AZETIDINE DERIVATIVES | VERNALIS (R&D) LTD. (GB) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918640-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | FAAH 2/4885MGLL 554/4885CYP1A2 35/4885 |
| US-20130331371-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | FAAH 2/4885MGLL 575/4885CYP1A2 38/4885 |
| US-12246014-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | FAAH 2/4885MGLL 577/4885CYP1A2 44/4885 |
| US-20120028953-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | FAAH 2/4885MGLL 562/4885CYP1A2 42/4885 |
| US-20150183769-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | FAAH 2/4885MGLL 575/4885CYP1A2 38/4885 |
| US-20170196864-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | FAAH 2/4885MGLL 554/4885CYP1A2 35/4885 |
| US-10383871-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | FAAH 2/4885MGLL 554/4885CYP1A2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.